Dr. Jeff Bland

There are three things that we collaboratively developed that have now stuck as clinical tools that I think are important to acknowledge as we move into this immune question. So let's just review quickly. I want to review quickly what really we have collaboratively developed as clinical therapeutic tools. Number one is gut restoration. We originally call it the four-hour program.

Now it's the five-hour program. We called it remove, replace, re-inoculate, repair. It was a way to actually intervene with patients that we could teach docs to understand pretty quickly that once they started doing this to the patients, the response they were getting was like, whoa. And then it caused them to see the paradigm shift.

Now it's the five-hour program. We called it remove, replace, re-inoculate, repair. It was a way to actually intervene with patients that we could teach docs to understand pretty quickly that once they started doing this to the patients, the response they were getting was like, whoa. And then it caused them to see the paradigm shift.

Now it's the five-hour program. We called it remove, replace, re-inoculate, repair. It was a way to actually intervene with patients that we could teach docs to understand pretty quickly that once they started doing this to the patients, the response they were getting was like, whoa. And then it caused them to see the paradigm shift.

So that was our first collaborative development of that algorithm that we called the 4-H program. Remove, replace, re-inoculate, repair. The next thing we worked on collaboratively.

So that was our first collaborative development of that algorithm that we called the 4-H program. Remove, replace, re-inoculate, repair. The next thing we worked on collaboratively.

So that was our first collaborative development of that algorithm that we called the 4-H program. Remove, replace, re-inoculate, repair. The next thing we worked on collaboratively.

Precisely. My first lecture, I recall, in fact, a doc sent me the notes from my first lecture on dysbiosis and leaky gut, 1985. So that was number one. Number two, which we collaborated on, which then also is tied to the immune system, has to do with the liver, and that's metabolic detoxification.

Precisely. My first lecture, I recall, in fact, a doc sent me the notes from my first lecture on dysbiosis and leaky gut, 1985. So that was number one. Number two, which we collaborated on, which then also is tied to the immune system, has to do with the liver, and that's metabolic detoxification.

Precisely. My first lecture, I recall, in fact, a doc sent me the notes from my first lecture on dysbiosis and leaky gut, 1985. So that was number one. Number two, which we collaborated on, which then also is tied to the immune system, has to do with the liver, and that's metabolic detoxification.

So what happens when stuff comes from the gut to the liver, which is the organ that has to process that, It has these processes that allow those molecules to be converted into non-toxic byproducts and be excreted that are called the detox pathways, phase one, phase two, phase three detox. We were the first people to really bring that up as a clinical therapeutic tool. Metabolic detoxification.

So what happens when stuff comes from the gut to the liver, which is the organ that has to process that, It has these processes that allow those molecules to be converted into non-toxic byproducts and be excreted that are called the detox pathways, phase one, phase two, phase three detox. We were the first people to really bring that up as a clinical therapeutic tool. Metabolic detoxification.

So what happens when stuff comes from the gut to the liver, which is the organ that has to process that, It has these processes that allow those molecules to be converted into non-toxic byproducts and be excreted that are called the detox pathways, phase one, phase two, phase three detox. We were the first people to really bring that up as a clinical therapeutic tool. Metabolic detoxification.

So that was another of our contributions to the field.

So that was another of our contributions to the field.

So that was another of our contributions to the field.

Yeah, I think that that's probably the thing that's helped it to go mainstream is when we develop the genetic ability to evaluate people's ability to detoxify drugs, both pharmacogenomics or pharmacogenetics, suddenly docs said, oh, that's right, I guess different people respond to drugs in different ways because they detoxify them in different ways.

Yeah, I think that that's probably the thing that's helped it to go mainstream is when we develop the genetic ability to evaluate people's ability to detoxify drugs, both pharmacogenomics or pharmacogenetics, suddenly docs said, oh, that's right, I guess different people respond to drugs in different ways because they detoxify them in different ways.

Yeah, I think that that's probably the thing that's helped it to go mainstream is when we develop the genetic ability to evaluate people's ability to detoxify drugs, both pharmacogenomics or pharmacogenetics, suddenly docs said, oh, that's right, I guess different people respond to drugs in different ways because they detoxify them in different ways.

It's the same metabolic pathways that are used to detoxify our foods and our foreign chemicals and xenobiotics. So suddenly now detox is in the main because of pharmacogenomics when docs have been criticizing that this is something specious.